Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Burns

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Oncology|August 29, 2003
InsulinomaAndrew R Burns, Alan P B Dackiw
Neuropharmacology|June 2, 2012
Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptorSujeenthar Tharmalingam, Andrew R Burns, Peter J Roy, et al.
Plos Neglected Tropical Diseases|April 6, 2017
The novel nematicide wact-86 interacts with aldicarb to kill nematodesAndrew R Burns, Rachel Bagg, May Yeo, et al.
Molecular Biology of the Cell|March 22, 2002
Wound closure in the lamellipodia of single cells: mediation by actin polymerization in the absence of an actomyosin purse stringJohn H Henson, Ronniel Nazarian, Katrina L Schulberg, et al.
Nature Chemical Biology|June 1, 2010
A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegansAndrew R Burns, Iain M Wallace, Jan Wildenhain, et al.
Nature Protocols|May 10, 2007
High-throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegansAndrew R Burns, Trevor C Y Kwok, Al Howard, et al.
Nature Communications|September 27, 2024
A rapid in vivo pipeline to identify small molecule inhibitors of amyloid aggregationMuntasir Kamal, Jessica Knox, Robert I Horne, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2026
A Cationic Amphiphilic Drug (CAD) Defense System in the Nematode <i>Caenorhabditis elegans</i>Levon Tokmakjian, Duhyun Han, Kateryna Sihuta, et al.
Microbial Cell Factories|December 31, 2022
Development of a yeast whole-cell biocatalyst for MHET conversion into terephthalic acid and ethylene glycolRaphael Loll-Krippleber, Victoria A Sajtovich, Michael W Ferguson, et al.
Nature Communications|March 31, 2023
Nemacol is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potentialSean Harrington, Jacob Pyche, Andrew R Burns, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Oncology|August 29, 2003
InsulinomaAndrew R Burns, Alan P B Dackiw
Neuropharmacology|June 2, 2012
Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptorSujeenthar Tharmalingam, Andrew R Burns, Peter J Roy, et al.
Plos Neglected Tropical Diseases|April 6, 2017
The novel nematicide wact-86 interacts with aldicarb to kill nematodesAndrew R Burns, Rachel Bagg, May Yeo, et al.
Molecular Biology of the Cell|March 22, 2002
Wound closure in the lamellipodia of single cells: mediation by actin polymerization in the absence of an actomyosin purse stringJohn H Henson, Ronniel Nazarian, Katrina L Schulberg, et al.
Nature Chemical Biology|June 1, 2010
A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegansAndrew R Burns, Iain M Wallace, Jan Wildenhain, et al.
Nature Protocols|May 10, 2007
High-throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegansAndrew R Burns, Trevor C Y Kwok, Al Howard, et al.
Nature Communications|September 27, 2024
A rapid in vivo pipeline to identify small molecule inhibitors of amyloid aggregationMuntasir Kamal, Jessica Knox, Robert I Horne, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2026
A Cationic Amphiphilic Drug (CAD) Defense System in the Nematode <i>Caenorhabditis elegans</i>Levon Tokmakjian, Duhyun Han, Kateryna Sihuta, et al.
Microbial Cell Factories|December 31, 2022
Development of a yeast whole-cell biocatalyst for MHET conversion into terephthalic acid and ethylene glycolRaphael Loll-Krippleber, Victoria A Sajtovich, Michael W Ferguson, et al.
Nature Communications|March 31, 2023
Nemacol is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potentialSean Harrington, Jacob Pyche, Andrew R Burns, et al.
Pageof 2